337 related articles for article (PubMed ID: 27545090)
1. Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer.
Xia Q; Zhang FF; Geng F; Liu CL; Wang YQ; Xu P; Lu ZZ; Xie Y; Wu H; Chen Y; Zhang Y; Kong W; Yu XH; Zhang HH
Cell Immunol; 2016 Dec; 310():89-98. PubMed ID: 27545090
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Zhang HH; Kong W; Yu XH
Vaccine; 2016 Aug; 34(38):4526-4535. PubMed ID: 27498213
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.
Xia Q; Geng F; Zhang FF; Liu CL; Xu P; Lu ZZ; Xie Y; Sun B; Wu H; Yu B; Kong W; Yu XH; Zhang HH
Immunopharmacol Immunotoxicol; 2017 Feb; 39(1):37-44. PubMed ID: 28004985
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.
Xia Q; Zhang FF; Geng F; Liu CL; Xu P; Lu ZZ; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Cancer Immunol Immunother; 2016 May; 65(5):613-24. PubMed ID: 27020681
[TBL] [Abstract][Full Text] [Related]
5. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer.
Geng F; Guo J; Guo QQ; Xie Y; Dong L; Zhou Y; Liu CL; Yu B; Wu H; Wu JX; Zhang HH; Kong W; Yu XH
Vaccine; 2019 Jul; 37(31):4382-4391. PubMed ID: 31202521
[TBL] [Abstract][Full Text] [Related]
6. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model.
Zhang FF; Qiao Y; Xie Y; Liu C; Wu H; Wu JX; Yu XH; Kong W; Zhang HH
Int Immunopharmacol; 2022 Nov; 112():109237. PubMed ID: 36152535
[TBL] [Abstract][Full Text] [Related]
7. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model.
Wen Y; Wang CT; Ma TT; Li ZY; Zhou LN; Mu B; Leng F; Shi HS; Li YO; Wei YQ
Cancer Sci; 2010 Nov; 101(11):2325-32. PubMed ID: 20804499
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour effects of a xenogeneic fibroblast activation protein-based whole cell tumour vaccine in murine tumour models.
Chen M; Xu G; Fan M; Jia H; Xiao L; Lang J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4182-4193. PubMed ID: 31722575
[TBL] [Abstract][Full Text] [Related]
10. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts.
Chen M; Xiang R; Wen Y; Xu G; Wang C; Luo S; Yin T; Wei X; Shao B; Liu N; Guo F; Li M; Zhang S; Li M; Ren K; Wang Y; Wei Y
Sci Rep; 2015 Sep; 5():14421. PubMed ID: 26394925
[TBL] [Abstract][Full Text] [Related]
11. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
[No Abstract] [Full Text] [Related]
12. Fibroblast activation proteins-α suppress tumor immunity by regulating T cells and tumor-associated macrophages.
Hou CM; Qu XM; Zhang J; Ding TT; Han W; Ji GC; Zhong ZH; Chen H; Zhang F
Exp Mol Pathol; 2018 Feb; 104(1):29-37. PubMed ID: 29273462
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
14. Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control.
Zhen Z; Tang W; Wang M; Zhou S; Wang H; Wu Z; Hao Z; Li Z; Liu L; Xie J
Nano Lett; 2017 Feb; 17(2):862-869. PubMed ID: 28027646
[TBL] [Abstract][Full Text] [Related]
15. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
16. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading.
Gottschalk S; Yu F; Ji M; Kakarla S; Song XT
PLoS One; 2013; 8(12):e82658. PubMed ID: 24349329
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
[TBL] [Abstract][Full Text] [Related]
18. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
